SG11201704427YA - Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal - Google Patents
Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signalInfo
- Publication number
- SG11201704427YA SG11201704427YA SG11201704427YA SG11201704427YA SG11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- sequence lacking
- modified bacteriophage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087052P | 2014-12-03 | 2014-12-03 | |
| PCT/US2015/063476 WO2016090022A1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704427YA true SG11201704427YA (en) | 2017-06-29 |
Family
ID=55273507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704427YA SG11201704427YA (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10722551B2 (en) |
| EP (1) | EP3227313B1 (en) |
| JP (2) | JP6730988B2 (en) |
| KR (1) | KR20170085132A (en) |
| CN (1) | CN107250154A (en) |
| AR (1) | AR102890A1 (en) |
| AU (1) | AU2015358504A1 (en) |
| BR (1) | BR112017011530A2 (en) |
| CA (1) | CA2969128A1 (en) |
| DK (1) | DK3227313T3 (en) |
| EA (1) | EA201791212A1 (en) |
| ES (1) | ES2910017T3 (en) |
| IL (1) | IL252426A0 (en) |
| MX (1) | MX2017007059A (en) |
| PH (1) | PH12017501004A1 (en) |
| PL (1) | PL3227313T3 (en) |
| PT (1) | PT3227313T (en) |
| SG (1) | SG11201704427YA (en) |
| TW (1) | TW201632542A (en) |
| WO (1) | WO2016090022A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104093414A (en) | 2011-11-29 | 2014-10-08 | 神经噬菌体制药股份有限公司 | Use of P3 of bacteriophage as amyloid binding agents |
| DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| EA030389B1 (en) | 2013-05-28 | 2018-07-31 | Проклара Байосайенсиз, Инк. | POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE g3p AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY |
| EP3227313B1 (en) | 2014-12-03 | 2022-02-09 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal |
| AU2019287623A1 (en) | 2018-06-15 | 2021-01-07 | Amyl Therapeutics Srl | General amyloid interaction motif (GAIM) |
| WO2024119183A1 (en) | 2022-12-02 | 2024-06-06 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
| EP0939121B2 (en) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TNF-binding proteins |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP3693671B2 (en) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | PEGylation of polypeptides |
| FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| CA2131003A1 (en) | 1992-05-26 | 1993-12-09 | Raymond G. Goodwin | Novel cytokine that binds cd30 |
| DE69833755T2 (en) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS |
| CN1202128C (en) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | Method for reducing immunogenicity of proteins |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| MXPA03007323A (en) | 2001-02-19 | 2003-12-12 | Merck Patent Gmbh | Artificial proteins with reduced immunogenicity. |
| ATE339446T1 (en) | 2001-03-08 | 2006-10-15 | Merck Patent Gmbh | MODIFIED HUMAN GRANULOCYTE MACROPHAGE COLONIES STIMULATING FACTOR (GM-CSF) WITH REDUCED IMMUNOGENICITY |
| DE10238846A1 (en) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Active fusion proteins and processes for their production |
| PT1853285E (en) | 2005-02-01 | 2011-06-06 | Univ Ramot | Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia |
| CA2642473A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| US20090105090A1 (en) | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
| CN101553567A (en) | 2006-07-21 | 2009-10-07 | 台拉维夫大学拉莫特 | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
| SG10201502661SA (en) | 2006-10-11 | 2015-05-28 | Antitope Ltd | T cell epitope databases |
| US20110182948A1 (en) | 2008-05-22 | 2011-07-28 | Beka Solomon | Method for treating disease characterized by plaque |
| MX2011005430A (en) | 2008-11-24 | 2011-10-28 | Univ Ramot | Method for treating parkinson' s disease using filamentous bacteriophage. |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| KR20140051840A (en) | 2011-03-11 | 2014-05-02 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Method for treating neurodegenerative tauopathy |
| CN104093414A (en) | 2011-11-29 | 2014-10-08 | 神经噬菌体制药股份有限公司 | Use of P3 of bacteriophage as amyloid binding agents |
| DK2906235T3 (en) * | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| EA030389B1 (en) * | 2013-05-28 | 2018-07-31 | Проклара Байосайенсиз, Инк. | POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE g3p AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY |
| EP3227313B1 (en) | 2014-12-03 | 2022-02-09 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal |
-
2015
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/en unknown
- 2015-12-02 EA EA201791212A patent/EA201791212A1/en unknown
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/en not_active Application Discontinuation
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/en active
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-02 TW TW104140347A patent/TW201632542A/en unknown
- 2015-12-02 PL PL15831011T patent/PL3227313T3/en unknown
- 2015-12-02 PT PT158310110T patent/PT3227313T/en unknown
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/en active Active
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en active Application Filing
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 ES ES15831011T patent/ES2910017T3/en active Active
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/en unknown
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/en active Pending
- 2015-12-03 AR ARP150103956A patent/AR102890A1/en unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/en not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791212A1 (en) | 2018-01-31 |
| TW201632542A (en) | 2016-09-16 |
| PL3227313T3 (en) | 2022-05-09 |
| EP3227313B1 (en) | 2022-02-09 |
| KR20170085132A (en) | 2017-07-21 |
| EP3227313A1 (en) | 2017-10-11 |
| AU2015358504A8 (en) | 2017-07-13 |
| US11723951B2 (en) | 2023-08-15 |
| BR112017011530A2 (en) | 2018-03-13 |
| US20180207231A1 (en) | 2018-07-26 |
| WO2016090022A8 (en) | 2017-06-22 |
| US10722551B2 (en) | 2020-07-28 |
| PH12017501004A1 (en) | 2017-12-18 |
| WO2016090022A1 (en) | 2016-06-09 |
| AR102890A1 (en) | 2017-03-29 |
| CA2969128A1 (en) | 2016-06-09 |
| MX2017007059A (en) | 2018-05-02 |
| JP2020073610A (en) | 2020-05-14 |
| CN107250154A (en) | 2017-10-13 |
| JP2017538407A (en) | 2017-12-28 |
| JP6730988B2 (en) | 2020-07-29 |
| AU2015358504A1 (en) | 2017-06-29 |
| US20210015895A1 (en) | 2021-01-21 |
| WO2016090022A9 (en) | 2016-08-25 |
| ES2910017T3 (en) | 2022-05-11 |
| PT3227313T (en) | 2022-04-12 |
| DK3227313T3 (en) | 2022-04-19 |
| IL252426A0 (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244019A1 (en) | Fusion proteins | |
| HK1253684A1 (en) | Conditionally active polypeptides | |
| HK1232136A1 (en) | P97-ids fusion proteins p97-ids | |
| SG11201704427YA (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal | |
| HK1258877A1 (en) | A novel endolysin polypeptide | |
| GB201417652D0 (en) | Improved encoding process using a palette mode | |
| HK1231493A1 (en) | Pharmaceutically relevant aromatic-cationic peptides | |
| HK1223285A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity g3p | |
| GB201418562D0 (en) | Peptides | |
| HRP20182029T1 (en) | Uti fusion proteins | |
| IL252902A0 (en) | Amino acid and peptide conjugates and uses thereof | |
| IL248276A0 (en) | Carbohydrate-binding protein | |
| GB201401877D0 (en) | Peptides | |
| HK1253316A1 (en) | Peptides | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| GB2528431B (en) | Improved encoding process using a palette mode | |
| GB201617799D0 (en) | Fusion polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide | |
| GB201420645D0 (en) | Peptides | |
| GB201412731D0 (en) | Peptides | |
| GB201410686D0 (en) | Peptides | |
| GB201409010D0 (en) | Peptides | |
| GB201405078D0 (en) | Peptides |